The Cost-Effectiveness and Value of Information of Three Influenza Vaccination Dosing Strategies for Individuals with Human Immunodeficiency Virus

Background Influenza vaccine immunogenicity is diminished in patients living with HIV/AIDS. We evaluated the cost-effectiveness and expected value of perfect information (EVPI) of three alternative influenza vaccine dosing strategies intended to increase immunogenicity in those patients. Methods A randomized, multi-centered, controlled, vaccine trial was conducted at 12 CIHR Canadian HIV Trials Network sites. Three dosing strategies with seasonal, inactivated trivalent, non-adjuvanted intramuscular vaccine were used in HIV infected adults: two standard doses over 28 days (Strategy A), two double doses over 28 days (Strategy B) and a single standard dose of influenza vaccine (Strategy C), administered prior to the 2008 influenza season. The comparator in our analysis was practice in the previous year, in which 82.8% of HIV/AIDS received standard-dose vaccination (Strategy D). A Markov cohort model was developed to estimate the monthly probability of Influenza-like Illness (ILI) over one influenza season. Costs and quality-adjusted life years, extrapolated to the lifetime of the hypothetical study cohorts, were estimated in calculating incremental cost-effectiveness ratios (ICER) and EVPI in conducting further research. Results 298 patients with median CD4 of 470 cells/µl and 76% with viral load suppression were randomized. Strategy C was the most cost-effective strategy for the overall trial population and for suppressed and unsuppressed individuals. Mean ICERs for Strategy A for unsuppressed patients could also be considered cost-effective. The level of uncertainty regarding the decision to implement strategy A versus C for unsuppressed individuals was high. The maximum acceptable cost of reducing decision uncertainty in implementing strategy A for individuals with unsuppressed pVL was $418,000 - below the cost of conducting a larger-scale trial. Conclusion Our results do not support a policy to implement increased antigen dose or booster dosing strategies with seasonal, inactivated trivalent, non-adjuvanted intramuscular vaccine for individuals with HIV in Canada. Trial Registration ClinicalTrials.gov NCT00764998.

[1]  Andrew J Dunning.  A model for immunological correlates of protection. , 2006, Statistics in medicine.

[2]  A. Osterhaus,et al.  Haemagglutination-inhibiting antibody to influenza virus. , 2003, Developments in biologicals.

[3]  G. Boivin,et al.  Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  P A West,et al.  Economic evaluation of strategies for the control and management of influenza in Europe. , 2002, Vaccine.

[5]  Sun-Young Kim,et al.  Cost-Effectiveness Analyses of Vaccination Programmes , 2012, PharmacoEconomics.

[6]  J. D. de Jong,et al.  Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. , 2000, Vaccine.

[7]  K. Nichol.  Efficacy and effectiveness of influenza vaccination. , 2008, Vaccine.

[8]  J. Brownstein,et al.  Efficacy of influenza vaccination in HIV‐positive patients: a systematic review and meta‐analysis , 2008, HIV medicine.

[9]  A. Adimora,et al.  Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis , 2006, BMC infectious diseases.

[10]  J. Singer,et al.  Immunogenicity Is Not Improved by Increased Antigen Dose or Booster Dosing of Seasonal Influenza Vaccine in a Randomized Trial of HIV Infected Adults , 2011, PloS one.

[11]  Vilija R. Joyce,et al.  Quality of Life of Patients With Advanced HIV/AIDS: Measuring the Impact of Both AIDS-Defining Events and Non-AIDS Serious Adverse Events , 2009, Journal of acquired immune deficiency syndromes.

[12]  D. Skowronski,et al.  Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? , 2008, The Journal of infectious diseases.

[13]  R. Willke,et al.  Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[14]  A. Osterhaus,et al.  On the relationship between mean antibody level, seroprotection and clinical protection from influenza. , 2009, Biologicals : journal of the International Association of Biological Standardization.

[15]  E. Cordero,et al.  Clinical presentation and prognosis of the 2009 H1N1 influenza A infection in HIV-1-infected patients: a Spanish multicenter study , 2010, AIDS.

[16]  Vilija R. Joyce,et al.  The concurrent validity and responsiveness of the health utilities index (HUI 3) among patients with advanced HIV/AIDS , 2009, Quality of Life Research.

[17]  G. Lüchters,et al.  Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? , 2004, Virus research.

[18]  K. Nichol,et al.  Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. , 2001, Archives of internal medicine.

[19]  Malbea A Lapete,et al.  Prevention and Control of Influenza Recommendations of the Advisory Committee on Immunization Practices ( ACIP ) , 2004 .

[20]  J. Sterne,et al.  Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies , 2007, AIDS.

[21]  E. Mills,et al.  A review of influenza vaccine immunogenicity and efficacy in HIV-infected adults. , 2008, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[22]  M. Schechter,et al.  Hospital utilization and costs in a cohort of injection drug users. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[23]  B. Gazzard,et al.  Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? , 2008, AIDS.

[24]  N. Cox,et al.  Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[25]  A. Burdorf,et al.  Measuring productivity changes in economic evaluation , 2005, PharmacoEconomics.

[26]  L. Chang,et al.  Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy. , 2010, The Cochrane database of systematic reviews.

[27]  I. Longini,et al.  Estimates of the US health impact of influenza. , 1993, American journal of public health.

[28]  S. Oka,et al.  Efficacy and Immunologic Responses to Influenza Vaccine in HIV-1-Infected Patients , 2005, Journal of acquired immune deficiency syndromes.

[29]  Lynnette Brammer,et al.  Estimates of US influenza‐associated deaths made using four different methods , 2009, Influenza and other respiratory viruses.

[30]  Bohdan Nosyk,et al.  Value of Information of a clinical prediction rule: Informing the efficient use of healthcare and health research resources , 2008, International Journal of Technology Assessment in Health Care.

[31]  A. Burdorf,et al.  Measuring productivity changes in economic evaluation: setting the research agenda. , 2005, PharmacoEconomics.

[32]  A. Gafni,et al.  Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. , 2006, Social science & medicine.

[33]  J. Myśliwska,et al.  Immunomodulating effect of influenza vaccination in the elderly differing in health status , 2004, Experimental Gerontology.

[34]  Richard D Moore,et al.  Contemporary costs of HIV healthcare in the HAART era , 2010, AIDS.

[35]  C. Bridges,et al.  Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  G. Rimmelzwaan,et al.  Response to 2009 Pandemic Influenza A (H1N1) Vaccine in HIV-Infected Patients and the Influence of Prior Seasonal Influenza Vaccination , 2011, PloS one.